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Abstract
Background: In South Asia a large number of patients seek treatment for TB from private
practitioners (PPs), and there is increasing international interest in involving PPs in TB control. To
evaluate the feasibility, effectiveness and costs of public-private partnerships (PPPs) for TB control,
a PPP was developed in Lalitpur municipality, Nepal, where it is estimated that 50% of patients with
TB are managed in the private sector. From the clinical perspective the PPP was shown to be
effective. The aim of this paper is to assess and report on the costs involved in the PPP scheme.
Methods: The approach to costing took a comprehensive view, with inclusion of costs not only
incurred by health facilities but also social costs borne by patients and their escorts. Semi-
structured questionnaires and guided interviews were used to collect start-up and recurrent costs
for the scheme.
Results: Overall costs for treating a TB patient under the PPP scheme averaged US$89.60. Start-
up costs per patient represented 12% of the total budget. Half of recurrent costs were incurred by
patients and their escorts, with institutional costs representing most of the rest. Female patients
tended to spend more and patients referred from the private sector had the highest reported costs.
Conclusion: Treating TB patients in the PPP scheme had a low additional cost, while doubling the
case notification rate and maintaining a high success rate. Costs incurred by patients and their
escorts were the largest contributors to the overall total. This suggests a focus for follow-up
studies and for cost-minimisation strategies.
Background
Tuberculosis is a leading cause of death worldwide [1]
and, although the incidence rate is higher in many African
countries, South Asia is the worst affected region in terms
of absolute numbers [2]. The internationally recom-
mended DOTS strategy [3,4] has been successfully imple-
mented in the public sector by many National
Tuberculosis Programmes (NTPs), but in the private sec-
tor the quality of care is generally very poor [5-7] This is a
cause for concern since the private sector is a major pro-
vider of TB care in South Asia, particularly in urban centres
[8]. There is currently considerable international interest
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in involving private practitioners (PPs) in TB control [9-
11]. However, there is little documented evidence of the
costs of such partnerships [12].
In Nepal, over 14,000 new cases of smear positive (i.e.
infectious) tuberculosis are notified each year [13], and it
has been estimated that in urban areas 50% of TB patients
were (poorly) managed in the private sector [14,15]. Fur-
thermore, with an average per capita income of US$378
[16], patients experience financial constraints to accessing
TB treatment. Following consultation of various policy
options, the Nepal NTP and the research team developed
a public-private partnership (PPP) for TB control in urban
Nepal. Lalitpur Municipality, a medium-sized city in the
Kathmandu valley with a population of about 200,000 –
a typical urban setting in the Nepalese context – was cho-
sen as a pilot site for this initiative.
In Lalitpur Municipality, District Public Health Office
(DPHO) is responsible for the TB control programme.
The DPHO took responsibility for day-to-day manage-
ment of the PPP scheme. This included providing training
for laboratory staff and Directly Observed Treatment
(DOT) supervisors, supervising workers involved in TB
control, ensuring supply and distribution of medicines,
and ensuring that five Treatment Centres (TCs) followed
standard NTP recording and reporting guidelines.
A semi-governmental hospital (Patan Hospital), three
NGOs (Yala Urban Health Programme (YUHP), Nepal
Anti-TB Association (NATA) and Care & Fair) and one pri-
vate nursing home (Hargan's Nursing Home, a private
clinic running private outpatient clinics in the mornings
and evenings [17]) were invited to become TCs for DOT.
An agreement was reached that microscopy services for
the PPP would be provided by a laboratory at Hargan's
Nursing Home, two laboratories run by NGOs, and a lab-
oratory at Patan hospital. DOT would be provided by all
five TCs. TCs had a memorandum of understanding with
the DPHO; other agreements were informal.
PPs were asked to refer patients to the DOTS centres rather
than providing DOT themselves; patients also self-
referred. Although not specifically targeted under the PPP
scheme, pharmacists could also refer suspected cases to
the TCs. PPs in the scheme were seen as complementary
to the public DOTS services, rather than replacing them,
and were encouraged to use referral facilities for TB labo-
ratory tests, DOT and complicated cases.
No financial incentives were paid to PPs, laboratories or
TCs, and no other incentives were provided other than
signs that confirmed participating DOTS centres were
accredited by the NTP. Treatment centres paid their own
staff's salaries. Patients paid the consultation fees when
they visited private practitioners. As is normal in Nepal,
the NTP covered costs of training, drugs for DOTS centres
(but not for individual private practitioners), laboratory
supplies (but not for private labs), and materials for
recording and reporting. Full details of the organisation of
the Lalitpur PPP are published elsewhere [17].
Two other groups were considered to be indirectly related
to the PPP scheme: volunteers and traditional healers. The
volunteers included in this study were unpaid local peo-
ple, selected by Lalitpur municipality and responsible to
the DOTS centre for community awareness, late patient
tracing and visiting PPs and private pharmacies who
referred TB cases to DOTS centres to deliver 'thank you'
follow-up letters. Volunteers also provided a mechanism
for the partnership to interact with PPs. They were pro-
vided training by YUHP in collaboration with the DPHO.
In this context traditional healers are local people who
practice ethnomedicine and other alternatives to western
medical practice and who are easily accessible by almost
all households in Nepal. Traditional healers in Nepal are
mainly faith-based and can be distinguished by the types
of services (e.g. astrology and herbal medicine) they offer
[18,19].
Clinical assessment demonstrated that the PPP met the
international target for treatment success, and increased
the number of TB patients receiving care under the DOTS
strategy. The establishment of the PPP showed an overall
increase of case notification of sputum positive patients in
the study area from 54/100,000 before implementation in
1998 to 102/100,000 following implementation in 2001.
Treatment success rates were over 90%, exceeding the
international target of 85%, and less than 1% of patients
defaulted. Details of the evaluation of the effectiveness of
the PPP, and lessons learnt, are published elsewhere
[20,21].
Although the PPP had been demonstrated to be clinically
effective, it was considered important to assess its costs to
allow others to assess feasibility of replicating the PPP
scheme elsewhere [22]. This paper reports details of this
study.
Methods
The study used a comprehensive approach to describing
costs, including costs incurred by DOT centres, patients
and their escorts, under the PPP scheme. This enables
assessment of the long-term sustainability of the PPP
[23,24].
Semi-structured interviews were used to collect data on
costs. Recurrent costs were collected during the financialBMC Public Health 2007, 7:84 http://www.biomedcentral.com/1471-2458/7/84
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year 2001–2002. All costs were collected in Nepali Rupees
(NRs), which were converted into US$ at the 2002
exchange rate of 1US$ = 78 NRs [25].
The costs for conducting this study (research project costs)
were treated as not directly related to the PPP and,
although reported in this paper, were not included as part
of costs for treating a TB patient.
All interviewees gave verbal informed consent prior to
being interviewed. Ethical approval for this study was
given by the Nepal Health Research Council.
Data on start-up and recurrent costs were collected in
three major fields: institutional costs, including costs
incurred by the DPHO and by each of five DOTS Centres
or TCs; patient-related costs including charges, direct travel
costs and opportunity costs for time lost in travel both by
patients and their escorts; and costs of involving volunteers in
the PPP.
Start-up costs were estimated per patient and recurrent
costs per patient per month. Costs were then calculated
for treating a TB patient on average throughout the whole
source of treatment. The average duration of treatment
was assumed to be 8 months across all three standard
treatment categories, although in practice this may vary
slightly depending on the treatment category (Figure 1).
This was done because the relatively small sample of
patient-reported data did not allow accurate estimates of
costs in each treatment category.
Table 1 shows the sample sizes and sampling duration
used in the study.
Two approaches for costing analysis were deployed, based
respectively on means and medians of costs within the dif-
ferent fields. Although both median and mean values are
reported in the paper, we emphasise the importance of
medians of costs: in our view these are more representa-
tive and allow study results to be more usefully extrapo-
lated to the rest of Nepal and to other similar contexts.
However, mean values have also been reported to permit
comparisons with other studies.
The following three sections provide the details of the data
collection methodologies to assess costs incurred by insti-
tutions, volunteers and patients respectively.
Institutional costs
The study assessed all start-up and recurrent institutional
costs related to the PPP scheme, including training, super-
vision, staff salaries, costs of medicines, managerial set-
up, logistical supplies, transportation and NTP central
administrative costs.
DPHO start-up costs included the managerial set-up of
the scheme as well as training of PPs, TC staff and volun-
teers. Administrative costs of training PPs and volunteers
were included in DPHO start-up costs. Recurrent costs
included costs of staff, procurement and delivery of med-
icines, refresher training courses and regular (4-monthly)
DOTS workshops involving staff from the TCs. All five TCs
worked independently and supervision and monitoring
was done by the DPHO.
Training costs were covered primarily by the DPHO.
Training costs reported under different TCs represent costs
necessitated by staff cover during training.
Costs of medicines for each treatment category of patients
were calculated based on standard Nepal NTP treatment
guidelines for each of three treatment categories of TB
patients. The costs of medicines reflect market prices in
2002/2003 and were estimated using government pro-
curement information provided by the NTP. These costs
were down-inflated by 2.9% – the official inflation rate for
2002 [26] – to obtain 2001/02 prices. Although in prac-
tice costs of medicines were covered by the Nepal NTP, in
order to simplify presentation of results, these were
regarded as part of the DPHO contribution. Costs of med-
icines exclude costs related to storage and transportation
of medicines from national to local levels; these were
included in other DPHO costs.
Volunteers' costs
A total of 23 volunteers were interviewed to obtain esti-
mates of their costs.
Whilst administrative costs of training volunteers and PPs
were regarded as part of DPHO start-up costs, the oppor-
tunity costs for the time spent on training was included in
volunteers' start-up costs. These were estimated as two
days salary (480 NRs, US$6.20) for 43 people.
The recurrent expenses incurred by volunteers were
recorded separately. These comprise costs reported for
three major types of activities, namely tracing patients,
visiting DOTS centres and meetings with PPs. Volunteers'
costs include actual travel expenses as well as the opportu-
nity costs of their time spent on the above activities.
Patients' costs
Patients' costs were obtained by interviewing patients
from each TC. Data were collected from patients registered
in TCs in the period May 2002 to January 2003. Ten
patients from each TC were randomly selected using the
NTP TB register and TB treatment cards. Of the 50 patients
interviewed, 27 were male and 23 were female; 26
patients were in treatment category I, 21 patients in cate-
gory III and 3 in category II.BMC Public Health 2007, 7:84 http://www.biomedcentral.com/1471-2458/7/84
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Patient's treatment path Figure 1
Patient's treatment path. Treatment paths of TB patients in Treatment Categories (CAT) 1, 2 and 3 are schematically pre-
sented. Only paths of patients involved in the PPP are shown. General treatment duration for all patients in CAT 1–3 is 8 
months; if follow-up sputum examination at 2/3 months is found positive then patient gets treatment for 9 months. Diagnosis in 
the private sector was done by PPs who were encouraged to use referral facilities for TB laboratory tests under the PPP 
scheme, and patients were referred to the Treatment Centres for the complete course of treatment under the PPP scheme.
TREATMENT
FAILURE / CHANGE
OF TREATMENT
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FIRST SYMPTOMS
Symptomatic treatment (often with traditional healers only).
DIAGNOSIS
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Patients' costs were collected across the following catego-
ries: costs incurred with traditional healers; charges during
diagnosis and treatment, which included consultation
and investigation charges with the latter comprising costs
of sputum smear microscopy, X-ray examination, routine
blood tests, Mantoux test and Lung Function Test (LFT);
and travel costs including opportunity costs for patients
and their escorts. Patients' costs include income losses due
to TB illness during the period from when they first sought
diagnosis from any source (including traditional healers)
until the diagnosis of TB was confirmed.
No intervention was made to bring traditional healers
into mainstream TB control; costs related to traditional
healers represent those reported by patients. Patients'
opportunity costs were estimated using actual  income
rates for each patient, with daily rates varying from
US$1.60 to US$3.08.
Results
Our estimates show that the median total cost involved in
treating a TB patient in the PPP scheme is US$89.60
including start-up costs (Table 2). The mean cost of
US$245.30 is 2.7 times higher than the median, largely
due to the considerable skew in the distribution of
patient-reported costs. As a result of this skew, we have
focused on median costs, although mean costs are also
reported for comparison purposes.
Our estimate of the overall cost of treating a TB patient
under the PPP scheme does not include research project
costs (start-up research project costs were estimated as
US$15 per patient and recurrent project costs were US$34
per patient per 8-month course).
The distribution of start-up and recurrent costs across
institutions, volunteers and patients is given in Table 2
and in the following three sections.
Start-up costs
Total start-up costs per patient were US$11.10, 64% of
which were DPHO costs, 32% TC costs and about 5% vol-
unteers' costs.
Start-up costs for both DPHO and TCs include four main
categories: training, procurement of equipment, manage-
rial set-up and social mobilisation (Table 3). About half
(47%) of DPHO start-up expenditure was on equipment,
the remainder comprising costs of training (32%) and
managerial set-up (22%). Equipment costs also formed
the majority (84%) of TCs costs, the remainder compris-
ing of training (7%), and social mobilisation (7%) and
managerial set-up (2%).
Recurrent costs
Recurrent costs show a more complex picture. As shown
in Table 2, the distribution of overall costs for treating one
TB patient comprised 40% for patient costs, 31% for
DPHO costs, 20% for TC costs, and 8% for volunteers'
costs.
Institutional recurrent costs
A breakdown of institutional recurrent costs is shown in
Table 3. Costs incurred by the DPHO and TCs fall into
four major categories: staff; procurement and transporta-
tion of medicines and (in the case of TCs) supplies; train-
ing-related (workshop) costs; and others including
utilities, maintenance and miscellaneous expenses.
DPHO recurrent costs were made up of costs for procure-
ment and distribution of medicines and supplies (70%),
staff (20%) and training-related costs (10%). Central
administrative costs of the Nepal NTP were estimated to
be $7.20/patient treated and were added to the DPHO
recurrent costs.
A breakdown of total reported TCs' recurrent costs shows
that 38% of these costs were incurred by Patan hospital
and that staff costs dominated (68% of total costs). The
Table 1: Sample size and sampling duration by field
Major fields of costs incurred Sample size (No of patients) Sampling duration in months (for recurrent costs)
1. Institutional costs, including
District Health Office 509 12
Treatment Centres, comprising 509 12
YUHP 191 12
Care & Fair 44 12
NATA 48 12
Patan Hospital 140 12
Hargan's NH 86 12
2. Volunteers  503 6
3. Patient-related costs 50 7 (median)
Sample sizes and sampling durations are given for the institutions, volunteers and patients.BMC Public Health 2007, 7:84 http://www.biomedcentral.com/1471-2458/7/84
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relatively low cost of supplies and transportation within
TCs is due to the fact that procurement and transportation
of medicines is covered by the DPHO. Care & Fair
reported the highest costs of utilities and others among
the TCs. These high costs are thought to be exceptional.
Volunteers' recurrent costs
As shown in Table 2, the costs per patient incurred by vol-
unteers are relatively low. Table 4 provides a breakdown
of this. Most volunteers' costs were incurred in attending
monthly meetings at TCs, followed by patient tracing and
regular visits to TCs, with a small fraction of costs incurred
in meeting with PPs.
Patients' recurrent costs
Costs reported by patients are broken down into 6 major
categories reflecting the diagnosis and treatment periods.
It is worth noting that medicines were provided to
patients free of charge: these costs are part of the institu-
tional recurrent costs. Costs of travel of both patients and
their escorts have been differentiated from charges for
diagnosis and treatment consultations.
Total reported patients' recurrent costs (Table 5) com-
prised patients' travel-related costs (78%) and charges
incurred during diagnosis (13%). Other costs included
costs with traditional healers, costs of escorts, treatment
charges and other expenses.
Medians of costs incurred with traditional healers and
other expenses were zero: that is, more than 50% of all
patients did not report such costs. The largest median
costs were for the diagnosis phase, and for opportunity
costs of treatment-related travel.
Overall diagnosis-related costs were further divided into
consultation charges (20%) and investigation-related
charges (80%). (Some patients were charged for sputum
lab tests, X-ray, and routine blood tests).
The majority of patients' non-medical costs comprised the
opportunity costs for time lost due to travel to and from
TCs, whilst financial transportation charges were reported
in about 20% of cases and represent 18% of total patient-
reported recurrent costs. The median cost of escorting
patients was higher for female patients (US$1.83) than for
male patients (US$0.11).
Treatment-related costs were a relatively small proportion
of overall patient-related costs: this is to be expected as the
NTP bears all the medical costs of treatment (for example,
TB drugs and sputum examination in public health facili-
ties). Though the median opportunity cost for the work-
ing time (rather than treatment time) lost by patients
directly due to TB was zero in this study, for individuals
these costs can represent a significant share of recurrent
costs. For example, two patients reported not being able to
Table 2: Summary of start-up and recurrent costs (US$)
Institutional Costs
DPHO All TCs Total Volunteer Costs Patient Costs TOTAL
No of Patients 509 509 503 50
Data collection period (months) 12 12 6 7
Median Mean Median Mean Median Mean Median Mean Median Mean Median Mean
Start-up costs
Total reported costs 3,625 8,107 11,731 264.6
Total costs per patient 7.10 7.10 3.50 15.90 10.60 23.00 0.50 0.50 0 0 11.10 (12%) 23.50 (9.6%)
Recurrent costs
Total reported costs 10,404 11,673 22,077 508 7,952
Total costs per patient per 8-month 
course
20.80 20.80 14.80 17.80 35.60 38.60 7.00 1.40 35.90 181.80 78.50 (88%) 221.80 (90.4%)
TOTAL START-UP AND 
RECURRENT COST
27.9 27.9 18.3 33.7 46.2 61.6 7.5 1.9 35.9 181.8 89.60 (100%) 245.30 (100%)
The breakdown of start-up and recurrent costs is presented with all costs being in US$.BMC Public Health 2007, 7:84 http://www.biomedcentral.com/1471-2458/7/84
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work for 2 and 3 years: the corresponding maximum cost
reported was US$1,755. Median patient and escort travel
expenses were zero, reflecting the proximity of TCs to
patients' homes/work places.
Patients' costs were also broken down by sex and source
of referral (Table 6). The highest costs were incurred by
patients referred from the private sector (US$56.30), fol-
lowed by patients referred from semi-government facili-
ties (US$44.50).
Overall costs incurred by female patients were considera-
bly higher than those reported by male patients. However,
costs reported by male patients who were self-referred and
referred from semi-government facilities were much
higher than female patients, although the relatively small
Table 4: Breakdown of total volunteers' recurrent costs (US$)
Cost per patient per 8-month course
Functions of volunteers Total reported cost Min Max Median Mean
Tracing patients 169 0 44.80 1.10 0.40
Visiting the TC 152 0.30 17.60 1.50 0.40
Meeting PPs 39 0 8.80 0.20 0.10
Monthly meeting at the TC 148 0.90 18.90 1.40 0.40
TOTAL VOLUNTEER COSTS 508 2.70 65.10 7.00 1.30
Volunteer costs are presented across their main functions.
Note 1: Medians per patient per 8-month course are given for each volunteer activity separately; therefore the total in the medians column is not 
the sum of median costs.
Table 3: Breakdown of institutional costs (all costs are in US$)
Institutional Costs
Treatment Centres
All TCs TOTAL
DPHO YUHP Care & Fair NATA Patan Hospital Hargan's NH Median Mean Median Mean
No of Patients 509 191 44 48 140 86 509
Start-up costs
Total reported:
Training 1,151 390 34 15 112 13 565
Equipment 1,693 179 0 213 6,410 11 6,814
Managerial set-up 780 86 9 1 63 0 159
Social mobilisation 0 5 0 359 205 0 569
Total reported costs 3,625 660 43 588 6,791 24 8,107 11,731
Total costs per patient 7.10 3.50 1.00 12.30 48.50 0.30 3.50 15.90 10.60 23.00
Recurrent costs
Total reported costs:
Staff 2,170 1,470 824 667 4,211 815 7,987
Medicines 5,992 0 0 0 0 0 0
Supplies and transportation 889 37 36 0 0 8 80
Training 987 58 26 16 39 30 168
Others 366 774 1,180 383 219 882 3,438
Total reported costs 10,404 2,339 2,066 1,065 4,469 1,735 11,673 22,077
Total costs per patient per 8-month course 20.80 8.20 31.30 14.80 21.30 13.40 14.80 17.80 35.60 38.60
TOTAL INSTITUTIONAL COSTS 27.90 18.30 33.70 46.20 61.60
The breakdown of institutional start-up and recurrent costs is presented with all costs being in US$
Note 1: DPHO training costs include only training of TC staff related to the PPP.
Note 2: Total cost per patient across all Treatment Centres was calculated as the median of TC costs. For individual TCs, costs per patient are the 
mean start-up costs.
Note 3: Recurrent costs per patient per 8-month course across all Treatment Centres was calculated as the median of TC costs. For individual 
TCs, costs per patient are the mean of recurrent costs per patient.BMC Public Health 2007, 7:84 http://www.biomedcentral.com/1471-2458/7/84
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sample sizes within each category (for example, only two
male patients were referred from semi-governmental facil-
ity and only one female patient was self-referred), may
mean these findings are unrepresentative.
Discussion
This study was designed to describe rather than compare
costs. The costs of treating a TB patient within the PPP are
estimated as US$89.60. The additional costs per patient to
the public sector (start-up costs US$10.60 and recurrent
US$35.60) associated with introduction of the scheme are
small for the benefit of doubling the case notification rate.
Two studies have been published that compare public sec-
tor costs and cost-effectiveness of TB control in PPP
schemes [27,28], but none giving costs incurred within
the routine Nepal NTP, so that we can not compare costs
from our study with routine costs.
Several studies have estimated the mean costs of treating
TB patients: in Pakistan estimated total costs of treating a
TB patient varying from US$102 to US$180 [29]; in India
total costs were estimated as US$120 [28], in Brazil the
cost of treating one new TB case was about $103 [30], and
in Ukraine the annual cost per TB patient was estimated as
about US$124 [31]. In our study the total estimated cost
of treating a TB patient calculated using medians
(US$89.60) is generally lower than in studies reported in
those studies whereas the cost calculated using mean val-
ues (US$ 239.90) is twice as high as most of these studies.
This difference may largely be due to the different meth-
odological approaches across the different studies – our
study did not consider research project costs as part of the
PPP and focused on median costs whereas the other stud-
ies used mean costs and mostly included project costs.
Furthermore, none of the studies except the one in Salva-
dor, Brazil considered patients' costs prior to diagnosis
and start of TB treatment, whereas our study included
income losses during the long delays in getting appropri-
ate diagnosis and starting on treatment as part of patients'
opportunity costs. Losses of income prior to diagnosis,
although being significant for some patients, were
reported only in a few cases and the use of medians helps
to reduce the possibility of cost estimates being skewed.
Whilst mean values of total costs are from 2.6 to 3.8
higher than those estimated in Bangladesh, the median
values of costs for treating one patient in our study are
similar to those estimated in Bangladesh – slightly higher
Table 5: Patient-related recurrent costs (US$)
Costs
Category of cost Number of patients 
reporting non-zero cost
Total reported Min value Max value Per patient per 8 months
Median Mean
Expenses with traditional healers 11 305 0 141 0.0 7.0
Diagnosis stage (excluding travel)
Consultation charges 48 196 0 16 1.5 4.5
Investigations 50 830 0.1 119 7.5 19.0
Sub-Total Diagnosis 1,026 0.2 132 10 23.4
Treatment (excluding medicines and travel)
Consultation charges 14 66 0 15 0.0 1.5
Investigations 31 57 0 12 0.2 1.3
Sub-Total Treatment 123 0 27 0.3 2.8
Patients' travel and opportunity costs
Travel expenses 11 184 0 37 0.0 4.2
Opportunity costs of days lost due to TB 18 5,152 0 1,755 0.0 117.8
Opportunity costs of travel time 50 842 1.8 202 8.8 19.3
Sub-Total Patients' Travel 6,179 2.4 1,780 3.8 141.2
Costs of escorts (travel time lost + cost of travel)
Travel expenses 6 73 0 40 0.0 1.7
Opportunity costs of travel time 33 146 0 44 0.9 3.3
Sub-Total Costs of Escorts 219 0 84 0.9 5.0
Other (miscellaneous) expenditures 5 100 0 36 0.0 2.3
TOTAL PATIENTS' COSTS 7,952 35.90 181.80
A breakdown of patient-related recurrent costs across main categories is presented. Frequency of costs from the total n = 50 is reported and total 
reported costs are shown versus median per patient's treatment course.
Note 1: The numbers of patients who reported costs are based on the total sample of 50.
Note 2: Minimum and maximum values and medians were derived for each type of costs separately and sub-totals in these columns are NOT the 
sums of their respective constituent costs.
Note 3: An increment from 7 months (median of patients' month at which costing data was collected) to 8 months (standard duration of treatment) 
was used to estimate mean values per patient per 8 monthsBMC Public Health 2007, 7:84 http://www.biomedcentral.com/1471-2458/7/84
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than in DOTS provided by BRAC (US$64) and lower than
in the government DOTS programme (US$96) [32].
Likewise, NTP central level administrative costs in our
study comprised 16% of the total public sector costs. This
is comparable to the situation in Bangladesh [32] where
public sector administrative costs including overheads
represented 10% of the total public sector costs.
A major component of overall costs was patients' or social
costs (Figure 2). Our finding that social costs constitute a
significant share of the total cost for treating a TB patient
was similar to the results from studies in India [28] and
Brazil [30]. In Nepal, the NTP provides medicines free of
charge, and these costs are regarded as public sector costs.
Donation of time by volunteers in our study (see section
4.2) explains the relatively low private sector costs.
Several studies demonstrate that the DOTS strategy is
more cost-effective than other approaches to TB control.
As shown in Figure 2, a study in India has also shown that
non-DOTS treatment of TB in the private sector is more
expensive than DOTS implemented using public-private
mix (PPM) [28]. Public-private partnerships in TB control
nowadays are proving to be increasingly cost-effective, as
demonstrated by studies in South Africa and India
[27,28], which suggest that PPPs to deliver DOTS can
remove a significant burden from the public health sector.
The dominance of recurrent costs over start-up costs mir-
rors the pattern generally seen when establishing a con-
ventional DOTS programme. This pattern was also seen in
Pakistan [29].
Institutional costs
Analysis of start-up costs across different TCs re-affirmed
a trend of larger facilities having generally higher institu-
tional overheads. A high start-up institutional cost per
patient was incurred by Patan Hospital (US$48.5) (Table
3). This is mainly explained by the construction of a TB
clinic for DOTS, which cost US$45.79 per patient.
We have also found generally high start-up costs per
patient incurred by one NGO. After a follow-up with the
TCs we found that this largely due to their inability to dis-
tinguish between start-up costs that were attributed to the
PPP scheme and other similar activities performed by the
institution.
On the other hand, the relatively low start-up costs of Har-
gan's NH arise because no costs reported for managerial
set-up and social mobilisation. This is explained by the
previous focus of this private clinic on TB control, leading
to a reduced need for start-up investments.
As for institutional recurrent costs, the DPHO and TCs
incurred roughly the same total costs, indicating a need
for strong financial commitment at all levels of the district
health system. Staff costs and costs for procurement and
distribution of medicines and supplies dominated within
total institutional costs, representing respectively 46%
and 32% of overall public recurrent costs.
Within TCs, the high recurrent costs per patient incurred
by one of the NGOs (US$31.30) are largely explained by
the relatively high cost of utilities (US$17.80 per patient),
which, again, suggests an inability to draw a clear line
between costs attributed to the PPP scheme and other
institutional overheads.
All other TCs incurred recurrent costs in the range
US$8.20 to US$21.30 per patient, which is considered
reasonable, given the number of patients administered in
Table 6: Recurrent patient-related costs by sex and source of referral (US$)
Source of referral Male Female ALL (USD)
No of cases Costs No of cases Costs
Median Mean Median Mean Median Mean
Public facility 13 32.72 128.44 10 43.02 99.00 32.72 115.64
Private sector 8 30.63 144.27 7 68.35 94.81 56.31 121.19
Self-referred 4 63.74 473.15 1 32.94 32.94 30.17 385.10
Semi government 2 105.47 160.42 5 44.47 472.84 44.47 383.58
All referral sources 27 32.72 186.57 23 55.27 176.13 35.94 181.77
A breakdown of patient-related recurrent costs by source of referral and sex is reported with No of cases indicating frequency of each. All costs 
are reported in US$).BMC Public Health 2007, 7:84 http://www.biomedcentral.com/1471-2458/7/84
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each TC which varied from 48 to 191 and the size of the
institution itself.
One of the messages which emerges from the above dis-
cussion is that high-cost institutions such as Patan Hospi-
tal (with high start-up costs) and Care and Fair (with high
recurrent costs) may have a significant impact on the over-
all costs of the PPP scheme. This effect is likely to diminish
if larger numbers of TCs are involved.
Volunteers' costs
The costs of involving volunteers in the PPP scheme
appear to be relatively low. Greater involvement of volun-
teers in the PPP scheme might be an interesting area to
explore further as a potential for cost-minimisation strat-
egies for the PPP scheme.
In this study we also assumed that volunteering had
opportunity costs for patient tracing, meetings with PPs
and visiting DOTS Centre, although in practice it was a
voluntary donation of time in contrast to the involuntary
time lost by TB patients. (Indeed interviews with volun-
teers indicate that it may be seen as an investment by indi-
viduals to gain subsequent employment opportunities).
However, caution may be necessary to avoid overloading
volunteers and to forestall volunteers' "compassion
fatigue".
Patients' costs
Patients' costs, including costs incurred by their escorts (in
the form of direct charges for services and less obvious
expenses such travel costs and time lost), represent the
majority of estimated recurrent costs per patient and, per-
haps, the most interesting area to explore in more detail.
One emerging conclusion is that the significant financial
burden on TB patients and their families may serve as a
factor restricting patients from entering into, and complet-
ing, the full course of treatment. Further research is
needed to confirm, further quantify and address this, and
potential cost minimisation strategies should address,
first of all, this aspect of recurrent budget costs.
Costs at diagnosis and treatment stages
A breakdown of patients' costs reveals a dominance of
diagnosis-related charges over treatment-related charges.
During treatment, consultation and investigation costs
were similar, whereas during diagnosis investigation costs
dominated.
Since the median month at which patients' costing data
was collected was 7 months, i.e. towards the end of the
Costs for treating a TB patient in Nepal, India, South Africa and Brazil Figure 2
Costs for treating a TB patient in Nepal, India, South Africa and Brazil. Costs of treating a TB patient are presented 
in three broad areas: social or patient-related costs; public sector or institutional costs; and private sector costs. The study 
results were compared with costs of PPPs in similar studies in India [28], Brazil [30] and South Africa [27]. Note 1: Mean values 
of patients' costs were affected by the inclusion of costs prior to diagnosis and TB treatment. Note 2: costs incurred in the 
Nepal study include costs prior to diagnosis and treatment, in contrast to the other studies shown here. Note 3: care needs to 
be taken when comparing mean values, since these may be highly skewed
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average 8-months treatment course, we can be confident
that most treatment-related charges were included in the
study results. Clearly, most of the patients' expenditure
occurred during diagnosis, whilst treatment-related
charges represent a small fraction of the total patient
expenses. The main conclusion emerging from this is that,
from a costing perspective, attention should be given to
cost-minimisation strategies during the diagnosis stage
and in particular investigation-related costs as a strategy to
reduce overall patient costs.
Travel-related costs
Transportation costs were reported in about 20% of cases.
This relatively low frequency is normal for the urban con-
text of our study. However, these, combined with the
opportunity costs of time lost due to travel, represent a
significant share of total costs within the study sample.
This is primarily because TB treatment involves multiple
visits to health facilities. If the decision is made to explore
ways of decreasing patients' costs, this is seen as a poten-
tial area on which to focus attention.
An important feature of our study is the inclusion of
patient opportunity costs due to time lost in travel which
accounted for a substantial proportion of overall costs.
We would therefore encourage other researchers to
include the opportunity costs for economic days lost due
to TB within social costs.
Costs of traditional healers
Another interesting finding is the relatively high costs
incurred by patients who seek assistance from traditional
healers. The frequency of these is relatively low (20%), but
costs incurred for traditional healers reported by patients
can be as high as US$141 (Table 5).
The traditional sector plays a significant role in determin-
ing patients' health in Nepal. Two potential strategies to
address this issue are to encourage a move away from
expensive healers providing ineffective treatment, or to
equip these healers with basic knowledge of TB and clear
instructions on referring potential TB cases.
Costs by gender
Treatment of female patients tends to cost more. This is
probably because of cultural values in Nepali society,
which require female patients to be escorted. Understand-
ing this gender differences in seeking TB care is another
area where research is needed.
Although this study was not designed to make statistical
comparisons between costs for men and women, the cost
differences between female and male patients represent
an interesting area for a follow-up study.
The high patient-related costs seen in this study are likely
to be similar for other TB control initiatives, whether Gov-
ernment or private. This suggests the need to address
patient costs, including issues of equity and gender related
to patient costs, more widely in TB control.
Conclusion
This study has demonstrated that this PPP is a financially
acceptable way of doubling TB case-finding while main-
taining high success rates. There is, therefore, evidence to
support scaling up this initiative in Nepal and in similar
contexts. However, TB Programme managers will need to
consider the degree to which PPs are willing to cooperate,
as well as other contextual factors. Three particular issues
are highlighted for consideration. Firstly, staff costs in the
assessed PPP scheme are low compared to a number of
other health systems. Secondly, an important feature of
the initiative is the use of unpaid volunteers. Where this is
not feasible, their roles may need to be replaced by paid
staff, increasing total costs. Lastly, social (patient) costs
estimated in this study, as in other TB control initiatives,
represent a significant share of total costs, indicating a
need to address issues of equity and gender to control
costs to TB patients and their families.
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